LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Akebia Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

2.99 -4.17

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.96

Max

3.13

Schlüsselkennzahlen

By Trading Economics

Einkommen

-5.9M

247K

Verkäufe

5.1M

62M

Gewinnspanne

0.395

Angestellte

181

EBITDA

-6.1M

7.4M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+123.64% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-56M

833M

Vorheriger Eröffnungskurs

7.16

Vorheriger Schlusskurs

2.99

Nachrichtenstimmung

By Acuity

15%

85%

27 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Akebia Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Sept. 2025, 23:59 UTC

Akquisitionen, Fusionen, Übernahmen

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8. Sept. 2025, 22:02 UTC

Wichtige Markttreiber

Microsoft Signs $17.4 Billion AI Deal With Nebius

8. Sept. 2025, 17:01 UTC

Wichtige Markttreiber

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8. Sept. 2025, 17:01 UTC

Wichtige Markttreiber

Tron Shares Rise After New Investment From Bravemorning

8. Sept. 2025, 16:14 UTC

Wichtige Markttreiber

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8. Sept. 2025, 16:13 UTC

Wichtige Markttreiber

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8. Sept. 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Sept. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8. Sept. 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8. Sept. 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8. Sept. 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8. Sept. 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8. Sept. 2025, 21:47 UTC

Wichtige Markttreiber

Microsoft Signs $17.4B AI Deal With Nebius

8. Sept. 2025, 21:33 UTC

Akquisitionen, Fusionen, Übernahmen

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8. Sept. 2025, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8. Sept. 2025, 21:19 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8. Sept. 2025, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8. Sept. 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

8. Sept. 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8. Sept. 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8. Sept. 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8. Sept. 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Sept. 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8. Sept. 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8. Sept. 2025, 16:59 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8. Sept. 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8. Sept. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. Sept. 2025, 16:16 UTC

Ergebnisse

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8. Sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. Sept. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Akebia Therapeutics Inc Prognose

Kursziel

By TipRanks

123.64% Vorteil

12-Monats-Prognose

Durchschnitt 7 USD  123.64%

Hoch 8 USD

Tief 6 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Akebia Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

2.345 / N/AUnterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

27 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat